Table H-11. Strength of evidence for final health outcomes for olderer versus newer antiepileptic drugs key question 1

| Outcome | Older AED | Newer AEDs | Number of Studies (RCTs, Obs) | Design | Risk of Bias | Quality Assessment | Summary of Findings |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Inconsistency | Indirectness | Imprecision | Quality | Importance |
| Time to first seizure | Carbamazepine | GabapentinLamotrigineOxcarbazepineTopiramateVigabatrin | 6 | RCTs | No serious risk of bias | Very serious inconsistency | No serious indirectness | Serious imprecision | Low | Important |
| Time to first seizure | Phenytoin | LamotrigineTopiramate | 2 | RCTs | No serious risk of bias | Serious inconsistency | No serious indirectness | Very serious imprecision | Low | Important |
| Time to first seizure | Valproic Acid | LamotrigineTopiramate | 3 | RCTs | No serious risk of bias | Serious inconsistency | No serious indirectness | Serious imprecision | Low | Important |
| Change from baseline in seizure frequency | Carbamazepine | Oxcarbazepine | 1 | RCT | No serious risk of bias | Not graded | No serious indirectness | Serious imprecision | Insufficient | Important |
| Change from baseline in seizure frequency | Phenytoin | Oxcarbazepine | 2 | RCTs | Very serious risk of bias | No serious inconsistency | No serious indirectness | Serious imprecision | Insufficient | Important |
| Change from baseline in seizure frequency | Valproic Acid | Oxcarbazepine | 1 | RCT | Very serious risk of bias | Not graded | No serious indirectness | Very serious imprecision | Insufficient | Important |
| 12 MonthSeizure Remission | Carbamazepine | GabapentinLamotrigineOxcarbazepineTopiramateVigabatrin | 2 | RCTs | No serious risk of bias | Very serious inconsistency | No serious indirectness | No serious imprecision | Low | Important |

|  |
| --- |
| **Table H-11. Strength of evidence for final health outcomes for older versus newer antiepileptic drugs key question 1 (continued)** |
| Outcome | Older AED | Newer AEDs | Number of Studies (RCTs, Obs) | Design | Risk of Bias | Quality Assessment | Summary of Findings |
| Inconsistency | Indirectness | Imprecision | Quality | Importance |
| 12 MonthSeizure Remission | Valproic Acid | LamotrigineTopiramate | 1 | RCT | No serious risk of bias | Serious inconsistency | No serious indirectness | No serious imprecision | Moderate | Important |
| 24 Month Seizure Remission | Carbamazepine | GabapentinLamotrigineOxcarbazepineTopiramate | 1 | RCT | No serious risk of bias | Serious inconsistency | No serious indirectness | No serious imprecision | Moderate | Important |
| 24 Month Seizure Remission | Valproic Acid | LamotrigineTopirmate | 1 | RCT | No serious risk of bias | Serious inconsistency | No serious indirectness | No serious imprecision | Moderate | Important |
| Seizure freedom | Carbamazepine | GabapentinLamotrigineOxcarbazepineTopiramateVigabatrinLevetiracetam | 20(15, 5) | RCTs and Observational | No serious risk of bias | Serious inconsistency | No serious indirectness | Serious imprecision | Low | Important |
| Seizure freedom | Carbamazepine Controlled or Sustained Release | LamotrigineLevetiracetam | 3 (2,1) | RCTs and Observational | No serious risk of bias | Serious inconsistency | No serious indirectness | No serious imprecision | Moderate | Important |
| Seizure freedom | Phenytoin | LamotrigineOxcarbazepineTopiramate | 5 (4, 1) | RCTs and Observational | No serious risk of bias | Serious inconsistency | No serious indirectness | No serious imprecision | Moderate | Important |
| Seizure freedom | Valproic Acid | LamotrigineOxcarbazepineTopiramate | 15(12, 3) | RCTs and Observational | No serious risk of bias | Serious inconsistency | No serious indirectness | No serious imprecision | Moderate | Important |

AED = antiepileptic drug; Obs = observational study; RCT = randomized controlled trial